No over-the-counter CBD balm has FDA approval to treat arthritis, neuropathy, inflammation, or chronic pain. Early studies can justify more research, but they do not validate every jar with a CBD label.
Topical and transdermal are not synonyms
A conventional topical is intended to act mainly at or near the skin. A transdermal system is designed to move an ingredient through the skin and into systemic circulation. Calling a product transdermal does not prove that it achieves a clinically useful blood concentration. That requires formulation-specific testing.
Balms often contain waxes and oils that remain on the skin. Creams and lotions contain more water. Roll-ons may add menthol, camphor, lidocaine, capsaicin, or fragrance. Any perceived effect can come from those ingredients, massage, cooling or warming sensations, CBD, or a combination.
What the evidence can and cannot show
Small trials and observational reports have examined cannabinoid topicals for selected pain and skin conditions. Study products, doses, diagnoses, and outcome measures vary. Findings from a prescription cannabinoid formulation, synthetic cannabinoid, or hemp seed oil should not be presented as proof that retail topical CBD works.
The 2025 AHRQ living review of cannabis for chronic pain concluded that evidence is product-specific and that many outcomes remain uncertain. Its topical evidence should not be generalized to all CBD balms. Our chronic pain research review explains the distinction between small average effects and individual response.
Drug claims change the regulatory question
The FDA has approved one purified CBD medicine for certain seizure disorders, not retail CBD cosmetics. A cream marketed only to moisturize skin is regulated differently from one claiming to treat arthritis, eczema, neuropathy, or inflammation. Disease-treatment claims require evidence and regulatory authorization that a cosmetic label does not provide.
Under the federal hemp changes scheduled to apply after December 11, 2026, product composition and container limits also matter. See the post-December 11 hemp guide for the statutory definitions and verify state rules separately.
How to compare a CBD topical
- CBD per container: Divide the total milligrams by the net weight or volume. A large jar can look potent while providing a low concentration.
- CBD per application: A total amount is not a dose unless the manufacturer defines and measures an application.
- Cannabinoid spectrum: Full-spectrum products may contain measurable THC. Broad-spectrum and isolate labels still need batch testing.
- Certificate of analysis: Match the product lot to testing for CBD, THC, solvents, pesticides, heavy metals, and microbes.
- Active non-CBD ingredients: Menthol, camphor, capsaicin, and lidocaine have their own effects, warnings, and concentration limits.
- Contact risks: Fragrance, essential oils, preservatives, and adhesives can irritate skin or trigger allergy.
- Claims: Treat promises as claims requiring evidence, not as label decoration.
Safer use
Patch-test a small area first. Do not apply to broken skin, eyes, mucous membranes, or near heat unless the label specifically permits it. Wash hands after application. Stop if burning, swelling, blistering, or a spreading rash develops. Keep all cannabis products away from children and pets.
Systemic exposure from a conventional balm may be lower than from an oral product, but it should not be assumed to be zero. A transdermal formula is specifically intended to increase absorption. Discuss use with a pharmacist or clinician if you take medicines with narrow safety margins, are pregnant or breastfeeding, or have significant liver disease. See the CBD medication interaction guide.
Sources
Scope: This page explains evidence and label evaluation. It does not endorse a product or replace diagnosis and treatment by a qualified clinician.